Consistent with what was asked of us and how the pharmacare plan would look according to the committee, it was our understanding that this public plan would supplant all other insurers for those particular drugs. Inherently, we assumed that this $3.9 billion that's not included in the formulary would continue to operate, but we made no further assumptions as to whether the private sector would continue to provide insurance for that or not.
On October 17th, 2017. See this statement in context.